| Prev Close | 66.21 |
| Open | 66.46 |
| Day Low/High | 66.45 / 67.32 |
| 52 Wk Low/High | 53.63 / 71.70 |
| Volume | 4.56M |
Astrazeneca PLC Sponsored ADR (AZN)
66.66
0.45
0.68
NASDAQ
| Exchange | NASDAQ |
| P/E Ratio | 51.70 |
| Div & Yield | N.A. (N.A) |
Buy Struggling Progenics and Dynavax Here
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
Novice Trade: EWU United Kingdom ETF
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Novice Trade: EWU ETF
This portfolio cannot be trusted to be diversified enough.
The Race to Cure Alzheimer's is On: These Are the Forerunners
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Latest Reasons to Avoid Alzheimer's Plays
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
I continue to see these names as bargains in the biotech and biopharma space.
Small Cap Biotech Bargains
Here are 2 small caps I continue to see as bargains in this space.
4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon
These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.
Watch Oncology Stocks Ahead of 2 Big Events
Data and industry conferences will likely be catalysts for shares in the space.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon
Surviving the age of Amazon is all there is to retailers' earnings.
Geron Shares Rise on Fast Track Designation -- Biotech Movers
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
3 Small Biotech Stocks Insiders Are Buying
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
These Stocks Are Ready to Reverse Course
This week's bullish and bearish reversal patterns.
AstraZeneca Shares Sink on Lackluster Mystic Drug Results
AstraZeneca shares are tanking.
China Was Right to Walk Away From Failed U.S. Trade Talks
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
These 3 Small Biotechs Have a Healthy Shot
Several firms hiked price targets on Portola into the $70s this week.
Give These 3 Small Biotechs a Shot
Several firms hiked price targets on Portola into the $70s this week.
Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies
U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.
Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again
Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Keep Trading AstraZeneca From the Long Side
The stock is headed toward a bullish golden cross.
Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps
Stocks declined on Tuesday as wild weather stifled activity and led to low volume.
Egalet Makes Friday's Biotech Mailbag
Why the name is sagging, and what it will take to spur the sector higher.
Cramer: Don't Give the Fed Credit
Most of the 10 best stocks of the bull market did it their way.
